Refractec Viewpoint Hyperopia Approval Limited To Temporary Treatment
This article was originally published in The Gray Sheet
Executive Summary
Refractec is positioning its Viewpoint CK conductive keratoplasty system as a potentially favorable alternative to LASIK for hyperopia (farsightedness) despite FDA approval limiting the product to "temporary" treatment
You may also be interested in...
Refractec CK Presbyopia Treatment Should Be Limited To 2.25D – FDA Panel
Refractec's CK Blended Vision radio frequency procedure should be approved to treat a narrower range of presbyobia than sought by the company, FDA's Ophthalmic Devices Panel recommended Feb. 6
Refractec CK Presbyopia Treatment Should Be Limited To 2.25D – FDA Panel
Refractec's CK Blended Vision radio frequency procedure should be approved to treat a narrower range of presbyobia than sought by the company, FDA's Ophthalmic Devices Panel recommended Feb. 6
Refractec ViewPoint Comparative Claims Questioned During Panel Review
Reservations raised by FDA's Ophthalmic Devices Panel regarding claims by Refractec about the less invasive nature of its ViewPoint conductive keratoplasty (CK) system compared with LASIK highlight the challenges the firm may face in differentiating its product from other refractive devices for treating hyperopia